Plain-English translation of NCT06394570 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
The STAR-EV trial is testing whether adding stereotactic radiation (a focused form of radiation therapy) to treatment with can improve outcomes for people with advanced bladder cancer who are not able to receive standard chemotherapy. Participants will receive the medication through an IV over several weeks, along with focused radiation sessions to the bladder, followed by surgery to remove the bladder. The study wants to see if this combination is safe and whether it helps eliminate the cancer before surgery.
Standard chemotherapy for advanced bladder cancer doesn't work for everyone—some patients have kidney problems, nerve damage, hearing loss, or heart conditions that make it unsafe. This trial is testing whether a newer medication combined with precise radiation might be an effective alternative for these patients.
You likely qualify if…
You likely don't qualify if…
You will receive three cycles of intravenous medication, given on day 1 and day 8 of each 3-week cycle. Radiation therapy will be added at some point during or after your medication cycles (the exact timing depends on which group you are assigned to), delivered in 5 focused sessions over about 2 weeks. After completing the medication and radiation, you will have surgery to remove your bladder and surrounding tissues. You will then be followed for one year after surgery to monitor your health and how well the treatment worked.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States